🏅 FDA Orphan Designation

Corifact

factor XIII concentrate (human)

Manufacturer: CSL Behring LLC

Indicated for:

Moderate hemophilia AOrphanCongenital factor XIII deficiency

FDA-Approved Indications (2)

Moderate hemophilia AOrphan Designation

For the routine prophylactic treatment of congenital factor XIII deficiency

Congenital factor XIII deficiency

Indicated for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency

Population: adult and pediatric

Indications & Usage

For the routine prophylactic treatment of congenital factor XIII deficiency ||| Indicated for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.